Conference abstract · 2018
Conference abstractPublished 1 Dec 2016
The story of Glatiramer acetate (Copaxone) in the treatment of multiple sclerosis: The potential for neuroprotection by immunomodulatory treatment
The Weizmann Institute of Science, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Multiple sclerosis (MS) is currently recognized as complex diseases in which inflammatory autoimmune reactivity in the central nervous system (CNS) results in demyelination, axonal and neuronal pathology. Treatment strategies thus aim to reduce the detrimental inflammation and induce neuroprotective repair processes. The synthetic copolymer Copaxone (Glatiramer acetate, GA), an approved drug for the treatment of MS, is the first and so far the only therapeutic agent to have a copolymer as its active ingredient. Using the animal model of MS, experimental autoimmune encephalomyelitis (EAE), the mechanism of action of GA was elucidated. These studies indicated that GA treatment generates immunomodulatory shift from the inflammatory towards the anti-inflammatory pathways, such as Th2-cells that cross the blood brain barrier (BBB) and secrete in situ anti-inflammatory cytokines as well as T-regulatory cells (Tregs) that suppress the disease. The consequences of GA treatment on the CNS injury inflicted by the disease were studied using immunohistochemistry, electron microscopy and magnetic resonance imaging. These analyses revealed reduced demyelination and neuro-axonal damages as well as neuroprotective repair processes such as neurotrophic factors secretion, remyelination and neurogenesis. These combined findings indicate that immunomodulatory treatment can counteract the neurodegenerative disease course, supporting linkage between immunomodulation, neuroprotection and therapeutic activity in the CNS. Recent Publications 1. R Aharoni (2015) Remyelination in multiple sclerosis: Realizing a long standing challenge. Expert Review of Neurotherapeutics. 22(41), 1-4. 2. R Aharoni (2015) Animal models of multiple sclerosis: Imperfect but imperative. Journal of Multiple Sclerosis 2(4), 2-4. 3. R Aharoni (2014) Immunomodulation neuroprotection and remyelination - The fundamental therapeutic effects of glatiramer acetate: A critical review. Journal of Autoimmunity. 54, 81-92. 4. R Aharoni (2014) Achievements and challenges in the current multiple sclerosis research. Austin Journal of Multiple Sclerosis & Neuroimmunology. 1(1), 1-2. 5. R From, R Eilam, D Bar-Lev, S Levin-Zaidman, M Tsoory, P LoPresti, M Sela, R Arnon and R Aharoni (2014) Oligodendrogenesis and Myelinogenesis during Postnatal Development - Effect of Glatiramer Acetate. Glia, 62, 549-665.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 1 Dec 2016
The story of glatiramer acetate (Copaxone) in the treatment of multiple sclerosis - The potential for neuroprotection by immunomodulat
Conference abstract · 2018
FROM BASIC RESEARCH TO DRUG DEVELOPMENT: THE STORY OF COPAXONE (GLATIRAMER ACETATE) IN THE TREATMENT OF MULTIPLE SCLEROSIS AND POTENTIAL APPLICATIONS FOR ADDITIONAL PATHOLOGIES
Conference abstract · 13 Oct 2016
The story of Copaxone (glatiramer acetate) in the treatment of multiple sclerosis and its new applications
Conference abstract
From basic research to drug development: The story of Copaxone (glatiramer acetate) in the treatment of multiple sclerosis and its new Applications
More from this journal
The newest in Neurological Disorders.
Commentary · 24 Feb 2026
Vertebrobasilar Dolichoectasia: A Meta-Analysis of Clinical Manifestations and Treatment Approaches
Commentary · 24 Feb 2026
Leveraging Multi-Dimensional Encoding in Single-Channel Haptic Feedback for Enhanced Two-Dimensional Control
Commentary · 24 Feb 2026
The Paradox of Seizure Frequency Reporting: Over counted, Underreported, and Its Clinical Implications
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalNeurological Disorders
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Rina Aharoni”

